RestorGenex Corp. (DFFN) Earning Somewhat Positive Media Coverage, Study Shows
News coverage about RestorGenex Corp. (NASDAQ:DFFN) has been trending somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. RestorGenex Corp. earned a daily sentiment score of 0.21 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.9018281596305 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of RestorGenex Corp. (DFFN) traded down 3.85% during midday trading on Friday, reaching $1.75. The company’s stock had a trading volume of 48,981 shares. The stock has a 50-day moving average price of $1.76 and a 200 day moving average price of $2.40. RestorGenex Corp. has a 52 week low of $1.34 and a 52 week high of $15.50. The stock’s market capitalization is $24.54 million.
About RestorGenex Corp.
Diffusion Pharmaceuticals Inc, formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company’s lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments.
Receive News & Ratings for RestorGenex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RestorGenex Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.